ELND005, scyllo-inositol, is an orally bioavailable small molecule drug candidate that crosses the blood-brain-barrier in humans. An extensive clinical program of Phase 1 and Phase 2 studies have been completed with ELND005 to support clinical development.
Michael Rafii, MD, PhD Assistant Clinical Professor Director, Residency Program
Alzheimer’s disease (AD) is the most common form of dementia, and this terminal, progressive brain disorder has no known cause or cure.